VistaGen Therapeutics, Inc. Announces Broad Stem Cell R&D Alliance With Toronto’s University Health Network and The McEwen Centre For Regenerative Medicine

SOUTH SAN FRANCISCO, Calif. & TORONTO--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., a biotechnology company using embryonic stem (ES) cell technologies to discover and develop new drugs for diabetes and neurological disorders, today announced an expansive ES cell research alliance with Toronto’s University Health Network (UHN), Canada’s leading research hospital, and its stem cell research affiliate, the McEwen Centre for Regenerative Medicine.